Updated:
Zomedica
Zomedica, led by CEO Larry Heaton, commercializes veterinary diagnostic platforms including TRUFORMA, PulseVet, and Assisi for the North American clinic...
Zomedica
Zomedica was founded in 2013 and, under CEO Larry Heaton, operates from Ann Arbor, Michigan. The company originally pursued pharmaceutical candidates for companion animals but restructured after pipeline setbacks. It now functions as a consolidator and commercializer of diagnostic hardware and consumables for veterinary clinics. The company owns a portfolio of diagnostic platforms spanning three main product lines: point-of-care biosensor assays under the TRUFORMA brand, therapeutic plasma exchange technology through the PulseVet acquisition, and ultrasound imaging devices via the Assisi product line. Zomedica targets the North American veterinary clinic market, generating recurring revenue from consumable cartridges and service contracts. Its distribution reaches clinics across the United States and Canada. Zomedica trades on the NYSE American exchange under the ticker ZOM. The firm does not disclose total assets under management in the manner of a fund, as it is an operating company. The product portfolio was built through a series of acquisitions beginning in 2020–2021, including the purchase of PulseVet and the Assisi technology, funded by share issuance rather than third-party limited partner capital. In May 2024, the company announced a share buyback program (per the firm, May 2024). Zomedica is structurally distinct from most Altss-tracked entities: it is an operating public company, not a fund or family office. Its capital deployment model is M&A and internal product scaling, funded by equity markets. The governance is a conventional public-company board structure, with succession tied to the CEO and senior commercial leadership rather than a single-family patriarch or general partner.
General information
Firm type
Asset Manager
Year founded
2013
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Ann Arbor
Corporate office
Ann Arbor, MI, United States
Principals
Larry Heaton
Chief Executive Officer
Sector focus
Frequently asked questions
Is Zomedica a fund or an operating company?
Zomedica is a public operating company listed on the NYSE American exchange. It does not deploy third-party capital through a fund structure. Its growth is funded through equity issuance and operating revenue.
What specific diagnostic technologies does Zomedica own?
The principal product lines are TRUFORMA (point-of-care biosensor assays), PulseVet (therapeutic plasma and pain management devices), and Assisi (ultrasound imaging). These were assembled through acquisitions completed in 2020 and 2021.
How does Zomedica generate revenue?
Revenue comes from the sale of diagnostic hardware to veterinary clinics and recurring sales of single-use consumable cartridges, primarily in the United States and Canada.
What is Zomedica's acquisition strategy?
The firm targets commercially available or near-market veterinary device technologies. It integrates acquired products into a shared sales and distribution platform rather than developing novel pharmaceutical compounds.
Who runs commercial and product decisions at Zomedica?
CEO Larry Heaton leads the company. The firm maintains a conventional public-company executive structure, including a COO and VP-level leaders for sales and product lines.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: